azenosertib (ZN-c3) / Zentalis Pharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
azenosertib (ZN-c3) / Zentalis Pharma
NCT04972422: A Phase 1b Study of ZN-c3 in Chinese Subjects

Recruiting
1b
38
RoW
ZN-c3, Study Drug
Zentera Therapeutics HK Limited
Solid Tumors
06/22
06/23
NCT05431582: Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Withdrawn
1
0
NA
ZN-c3, Bevacizumab, Avastin™, Anti-VEGF monoclonal antibody, rhuMAb-VEGF, Pembrolizumab, KEYTRUDA®
M.D. Anderson Cancer Center, Zentalis Pharmaceuticals
Tumors, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer
12/22
12/22
ZN-c3-001, NCT04158336: A Study of ZN-c3 in Participants With Solid Tumors

Recruiting
1
146
US
ZN-c3, Study Drug
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Solid Tumor
05/23
08/23
ZN-c3-002, NCT04516447: A Study of ZN-c3 in Patients With Ovarian Cancer

Jul 2023 - Dec 2023: Data from trial in combination with chemotherapy for platinum-resistant ovarian cancer
Recruiting
1
140
Europe, US, RoW
ZN-c3, Study drug, Azenosertib, Carboplatin, Pegylated liposomal doxorubicin, Paclitaxel, Gemcitabine, Bevacizumab
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
12/24
02/27
NCT04005690: Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Recruiting
1
80
US
Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Onvansertib, 'PLK1 Inhibitor PCM-075, NMS-1286937, PCM 075, PCM-075, PLK-1 Inhibitor PCM-075, Polo-like Kinase 1 Inhibitor NMS-1286937, Polo-like Kinase 1 Inhibitor PCM-075, Azenosertib, ZN-c3, KP-2638, C29H34N8O2
OHSU Knight Cancer Institute, American Association for Cancer Research, Oregon Health and Science University, Genentech, Inc., Cardiff Oncology
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
06/26
02/28
NCT06364410: Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Not yet recruiting
1
48
NA
Azenosertib, Wee1 Inhibitor ZN-c3, ZN c3, ZN-c3, ZNc3, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516
National Cancer Institute (NCI)
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastric Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm
03/26
03/26
NCI-2022-03599, NCT05368506: ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer

Withdrawn
1
14
NA
Wee1 Inhibitor ZN-c3, ZN c3, ZN-c3, ZNc3
OHSU Knight Cancer Institute, Oregon Health and Science University
Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
09/24
07/25
NCT06109883: LB-100 (PP2A Inhibitor) and Azenosertib (WEE1 Inhibitor) in Metastatic Colorectal Cancer Patients

Not yet recruiting
1
43
NA
LB-100, PP2 inhibitor, Azenosertib, WEE1 inhibitor, ZN-c3
The Netherlands Cancer Institute
Metastatic Colorectal Cancer
11/26
11/26

Download Options